Published in Mol Cancer Ther on April 01, 2008
Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagn Pathol (2011) 1.09
The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. J Chromatogr A (2009) 1.06
Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. Yonsei Med J (2010) 1.05
Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol (2009) 0.85
Biomarkers in triple negative breast cancer: A review. World J Clin Oncol (2015) 0.84
Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center. PLoS One (2015) 0.82
Genetic characterization of breast cancer and implications for clinical management. J Cell Mol Med (2009) 0.81
Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors. BMC Cancer (2015) 0.78
Diagnostic utility of snail in metaplastic breast carcinoma. Diagn Pathol (2010) 0.76
Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer. Cancer Sci (2015) 0.76
Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas (2013) 0.76
Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma. Oncotarget (2016) 0.75
Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Arch (2016) 0.75
[Genome-wide expression profiling as a clinical tool: are we there yet?]. Pathologe (2009) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol (2004) 2.61
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol (2007) 2.48
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Gastrointestinal stromal tumor: 5 years later. Cancer (2005) 2.40
EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol (2005) 2.37
Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol (1999) 2.12
Metaplastic breast carcinomas are basal-like tumours. Histopathology (2006) 1.80
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. Eur J Cancer (2006) 1.66
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc (2002) 1.59
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res (2005) 1.59
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol (2006) 1.57
p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol (2004) 1.57
Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol (2005) 1.55
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res (2006) 1.53
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther (2005) 1.49
Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol (2006) 1.48
KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res (2004) 1.28
Classification of metaplastic carcinomas of the breast. Pathol Annu (1992) 1.28
Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med (2005) 0.79
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet (2004) 6.85
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin (2005) 4.06
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest (2005) 3.51
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol (2013) 3.24
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Small cell lung cancer. Mayo Clin Proc (2008) 2.99
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med (2009) 2.97
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst (2008) 2.94
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res (2008) 2.76
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol (2006) 2.74
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res (2003) 2.73
Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res (2007) 2.61
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Pathophysiology and treatment of hot flashes. Mayo Clin Proc (2002) 2.56
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol (2008) 2.55
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52
Centrosome amplification and the development of cancer. Oncogene (2002) 2.51
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
Genetics of adult glioma. Cancer Genet (2012) 2.48
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol (2014) 2.42
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol (2006) 2.28
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res (2006) 2.27